Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
AstraZeneca’s Fasenra (benralizumab) has received U.S. approval for treating adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and potentially fatal immune-mediated vasculitis that can damage multiple organs. This…
FluMist has become the first self-administered influenza vaccine approved in the US. This needle-free nasal spray can now be self-administered by adults up to 49 years old or given by…
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral medication, demonstrating a significant reduction in the…
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions recommending…
A team of researchers from City of Hope® and The University of Texas M.D. Anderson Cancer Center has shared promising safety and efficacy results from a Phase 1 trial involving…
The Family Heart Foundation, a prominent research and advocacy organization, has announced the successful completion of its Flag, Identify, Network, and Deliver™ “FIND Lp(a)” machine learning model. This groundbreaking tool…
Organon (NYSE: OGN), a global healthcare company dedicated to improving women’s health, has announced a definitive agreement to acquire Dermavant Sciences, a subsidiary of Roivant (NASDAQ: ROIV). Dermavant specializes in…
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative, next-generation treatments, recently shared key clinical accomplishments…
Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at…
Takeda (TOKYO:4502/NYSE: TAK) has announced a commitment of JPY 4.6 billion (approximately USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners. This investment is part of Takeda’s…
Glycomine, Inc., a biotechnology company specializing in treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GLM101, a mannose-1-phosphate…